Tonnesen 2003.

Methods	BUPROPION Randomized controlled trial Setting: 28 clinical trial centres in 8 European countries, Australia, NZ Recruitment: community volunteers
Participants	710 smokers >= 10 CPD; 51% F, av. age 42, median CPD 20, no details of depression history
Interventions	1. Bupropion SR 300 mg/day for 7w 2. Placebo Both arms: brief motivational support at weekly clinic visits and telephone support during follow up. 11 clinic visits and 10 phone calls scheduled.
Outcomes	Abstinence at 52w (prolonged from w4) Validation: CO <= 10 ppm
Notes	First included 2003 as Tonstad 2001. ITT population defined as those taking at least one dose of study medication excludes 3 randomized participants Funding: GlaxoSmithKline
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"GlaxoSmithKline created a randomization schedule in a 3 : 1 bupropion: placebo ratio. Each centre received a list with treatment numbers and subjects were consecutively assigned a treatment number at the baseline visit."
Allocation concealment (selection bias)	Low risk	As per above. "GlaxoSmithKline supplied bupropion SR 150 mg and placebo‐to‐match tablets for oral administration as white, film‐coated tablets."
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind but methods not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	9% of bupropion SR and 12% placebo were lost to follow‐up.